|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity against bladder cancer.
|
31231785 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The VEGF gene rs3025039C/T and rs833052C/A variants may contribute to the risk of developing BCa, especially in Asian descendants.
|
30609111 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bioinformatics, RNA immunoprecipitation and luciferase reporter assays were used to verify the relationship among circ0001429, miR-205-5p and VEGFA in bladder cancer.
|
30909190 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To ascertain whether VEGF polymorphisms are associated with the susceptibility to BCa, we conducted this systematic review and meta-analysis.
|
30849545 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
DHFR and VEGF are expected to become novel therapeutic targets for the treatment of bladder cancer.
|
30655756 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, subgroup analysis based on cancer types demonstrated that significantly increased association was found between VEGF rs699947 polymorphism and the risk of bladder cancer (BCa) under heterozygous genetic model (OR = 1.48, 95%CI = 1.17-1.89).
|
30195633 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survival analysis revealed that the expression levels of ACTA2, CCNB1, CDC20 and VEGFA were related to the prognosis of patients with bladder cancer.
|
30533316 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
|
29277778 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Haplotype-based association of Vascular Endothelial Growth Factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population.
|
29959793 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data from bioinformatic and luciferase reporter gene assays identified that miR-5195-3p targeted the mRNA 3'-UTR of Krüppel-like factor 5 (KLF5), which is a proven proto-oncogene in bladder cancer. miR-5195-3p sharply reduced KLF5 expression and suppressed the expression or activation of its several downstream genes that are kinases improving cell survival or promoting cell cycle regulators, including ERK1/2, VEGFA, and cyclin D1.
|
28109084 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
VEGF expression in bladder cancer is associated with REG1α expression and recurrence.
|
28209239 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with AE-AS markedly decreased the protein accumulation and transcriptional activity of HIF-1α, vascular endothelial growth factor (VEGF) expression/secretion, and VEGFR2 phosphorylation in hypoxic human bladder cancer (T24) cells and tumor tissues accompanied by a reduction of tumor growth.
|
28710377 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.
|
28687357 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that the A allele of rs699947 and the A allele of rs833052 within VEGF gene, interaction between rs2010963 and smoking, haplotype containing the rs2010963- C and rs833052- A alleles were all associated with increased bladder cancer risk.
|
28206971 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.
|
28423532 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interruption of the IL1→AR→HIF1α→VEGFa signals with inhibitors of HIF1α or VEGFa partially reversed the enhanced bladder cancer cell invasion.
|
27196763 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A correlation between bladder cancer and MVD and VEGF suggest that the latter can serve as markers for therapeutic guidance.
|
25792473 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results indicate that KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription and suggest that KLF5 could be a novel therapeutic target for angiogenesis inhibition in bladder cancer.
|
26544730 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results at two time points showed that MMP9 and VEGFA genes expression was increased in patients with moderately differentiated BCa (p=0.029), and advanced pathologic stage (p=0.048), respectively.
|
26197083 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study clearly demonstrates that the predominant effect of this combination is the reduction of signaling molecules including STAT3, STAT5b, IGF-1R, VEGF and VEGF-R2 which are involved in the growth, progression and metastasis of human bladder cancer.
|
24402583 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of GATA3 in the bladder cancer lines (5637, TCC-SUP, J82) resulted in promotion of cell migration and invasion as well as increases in the expression of their related molecules, such as vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9, and the activity of MMP-2 and MMP-9.
|
24448324 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
VEGF and VEGFR1 mRNA levels were significantly higher in bladder cancer specimens than that of normal mucosa (for VEGF, p<0.001; for VEGFR1, p=0.02).
|
23749886 |
2013 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, they suggest that endocan might serve as a useful biomarker to monitor disease progression and the efficacy of VEGF-A-targeting therapies in patients with bladder cancer.
|
23243026 |
2013 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggested that polymorphism -2578C/A and -1001G/C in the promoter of VEGF gene may play a significant role in mediating the bladder cancer risk, whereas VEGF-2549I/D genotype appears to be protective for BC.
|
23430447 |
2013 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that overexpression of survivin and VEGF accompany a higher risk of BTCC recurrence, making survivin and VEGF biomarkers for predicting the relapse of bladder cancer.
|
23613251 |
2013 |